By Fineline Cube Mirxes Holding Company Ltd, a Singapore-headquartered RNA technology company specializing in blood-based miRNA test kit products, has successfully closed a Series D financing round, raising USD 50 million. The funding round was supported by a consortium of existing and new investors, including Beijing Fupu, in which the Zhejiang Anji Economic Development Zone holds a majority stake, EDB Investments Pte Ltd, the Agency for Science, Technology and Research, Japan’s Mitsui & Co., Ltd, and NHH Venture Fund. The proceeds from this round will be directed towards the research and development (R&D) of cancer early screening pipelines and their commercialization in the Asia-Pacific region.
Expanding Adoption of GASTROClear and Pipeline Development
Founded in 2014, Mirxes intends to use the new investment to increase the adoption and penetration of its flagship stomach cancer blood test, GASTROClear, in key Asia-Pacific markets such as Southeast Asia, China, and Japan. The company also aims to accelerate the development and commercialization of its clinical pipeline, which includes a blood-based colorectal cancer screening test and a multi-cancer early detection test under Project CADENCE. This ambitious project is focused on developing a single blood test for the early detection of nine high mortality cancers, leveraging the company’s first-in-class RNA technology and other complementary biomarker technologies.
Listing Application with HKEX and Future Outlook
In addition to securing the Series D funding, Mirxes has filed a listing application with the Stock Exchange of Hong Kong Limited (HKEX) under Chapter 18A of the Rules Governing the Listing of Securities on HKEX. This move signifies the company’s commitment to expanding its presence in the capital markets and further solidifying its position as a leader in the RNA technology space.-Fineline Info & Tech